Pharma Journalist -

AstraZeneca’s Farxiga (dapagliflozin) has been approved by the US Food and Drug Administration (FDA) to improve glycaemic control in paediatric patients with type-2 diabetes (T2D)…
Read More...

Flagship Pioneering and ProFound™ Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a multitude of diseases, announced a…
Read More...

IQVIA announced the launch of One Home for Sites, a new technology platform that acts as a single sign-on and a single dashboard for the key systems and tasks a clinical research site…
Read More...

GSK plc announced that it has acquired Elsie Biotechnologies, a San Diego-based private biotechnology company dedicated to unlocking the full potential of oligonucleotide therapeutics,…
Read More...

Cycle Pharmaceuticals Ltd, a rapidly growing pharmaceutical company focused on treatments for the underserved rare disease patient community, today confirmed that it made a proposal to…
Read More...

In the wake of significant achievements in synthetic peptide therapeutics, such as Novo Nordisk’s $6 billion peptide expansion, Merck’s advancements in macrocyclic peptides, and…
Read More...

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions,…
Read More...

QIAGEN announced the launch of its new digital PCR (dPCR) Custom Assay Design Tool for copy number variation (CNV) analysis for use on its digital PCR platform QIAcuity and several…
Read More...

Alphamab Oncology announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and collaboration…
Read More...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer,…
Read More...